Advinus Therapeutics Ltd and Takeda Pharmaceutical Company Limited have entered into an agreement to initiate a three-year discovery collaboration focused on novel targets for major therapeutic areas including Inflammation, CNS, and metabolic diseases. In this collaboration, Advinus is responsible for leading the programmes to create optimal IND ready compounds for pre-defined targets.
Under the terms of the agreement, Takeda will receive worldwide commercial rights to drug candidates emerging from this alliance. Advinus will receive guaranteed research funding of $36 million over the term of the collaboration, $9 million in milestones leading to candidate selection, and is eligible to receive future clinical and regulatory milestone payments of up to $45 million per product, plus royalties on product sales worldwide.
“Collaboration with Advinus is one of our initiatives to enhance our research productivity,” said Dr Paul Chapman, general manager of the Pharmaceutical Research Division of Takeda.
“We are very excited to partner with Advinus as they have innovative approaches to efficiently generate INDs that will further strengthen Takeda’s drug discovery capabilities, while also enhancing our pipeline,” added Dr Chapman.
“Advinus team is delighted that its biggest ever collaboration has been made possible by Takeda's visionary leadership, and their confidence in the founding principles that aim to create these new R&D opportunities. Takeda and Advinus teams together will advance globally networked innovation for addressing key Pharma R&D issue – R&D productivity for better return on R&D investments,” said Dr Rashmi Barbhaiya, chief executive officer of Advinus.
Takeda Pharmaceutical is located in Osaka, Japan and Advinus Therapeutics, promoted by the Tata Group is a privately held research-based pharmaceutical company focused on the discovery and development of proprietary new medicines for metabolic and inflammatory diseases. The latter’s discovery unit located in Pune is fully integrated from hit to preclinical candidate. Advinus Development Centre in Bangalore offers an integrated service platform for process chemistry, DMPK, clinical pharmacology, safety assessment, analytical R&D, bioanalytical and pre-formulation development.